KOSDAQBiotech & Pharma256940

Keeps Biopharma

₩4,695 0.00%2026-11-18 close
Market Cap
₩94.3B
Turnover
₩95,825,155
Volume
20K
Shares out.
20.1M
PER
—
PBR
1.7×
EPS
-₩811
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales Scale Up Fast, Profit Recovery Still Pending

Keeps Biopharma's cumulative sales passed its full-year 2025 level within nine months on pharma and biotech M&A, but three straight loss-making operating quarters leave profitability as the open question.

  1. 1

    The pharma and biotech unit drove growth, lifting its share of cumulative sales to 40% in the first nine months of 2026 (preliminary, reported November 16, 2026).

  2. 2

    Disclosed sales rose for three straight years from 2023 to 2025, yet the operating margin fell to 0.9% in 2025.

  3. 3

    The operating loss widened from KRW 664 million in Q1 2026 to KRW 4.98 billion in Q3 2026.

  4. 4

    The pipeline centers on the anticancer candidate Idetrexed and the oral peptide platform Oraloid, while global licensing is still described as a discussion stage.

  5. 5

    Debt-to-equity (total liabilities ÷ total equity) rose from 63.7% in 2022 to 187.0% in 2025, raising leverage.

02

Business structure

Keeps Biopharma runs three business lines: display and semiconductor process equipment, battery materials, and pharma and biotech. The fastest-growing unit is pharma and biotech.

According to the company, its cumulative pharma and biotech sales for the first nine months of 2026 were KRW 69.3 billion, up 92% year on year, and its share of total sales rose from 30% to 40%. The unit covers anticancer drug development and distribution and an oral drug-delivery platform.

The anticancer-focused subsidiary Big Think reported cumulative sales of KRW 9.6 billion and cumulative operating profit of KRW 300 million for the first nine months of 2026, turning profitable.

In February 2026 a subsidiary acquired 92% of L-Pharm, an anticancer drug distributor reported at about KRW 30 billion in annual sales. The core new drug is Idetrexed, a folate receptor-targeted anticancer candidate in-licensed through the US subsidiary Algok Bio.

A combination trial led by the UK Institute of Cancer Research is ongoing, and domestic Phase 2 IND approval has been reported. The Oraloid platform turns injectable peptides into oral forms, and preclinical oral insulin data were presented at EASD in September 2026.

The battery unit, Battery Solutions, is a used-battery recycler, which the company says faces entry barriers as seven domestic players hold a near-monopoly. Its recycled material is supplied under annual contracts, so buyers are fixed at the start of each year.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩40.9B₩1.4B3.5%
2025Q4₩45.2B₩1B2.2%
2026Q1₩59.4B-₩700M−1.1%
2026Q2₩74.9B-₩2.4B−3.2%
2026Q3₩68.4B-₩5B−7.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩14.6B-₩8.6B-₩11.4B−58.9%−21.4%63.7%
2023₩92.1B₩3.1B₩3.9B3.3%6.9%100.2%
2024₩127.6B₩6.2B₩1.1B4.9%2.2%161.3%
2025₩170.1B₩1.6B-₩9.8B0.9%−15.8%187.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On disclosed annual figures, sales rose from KRW 14.6 billion in 2022 to KRW 92.1 billion in 2023 (up 530.3%), KRW 127.6 billion in 2024 (up 38.5%), and KRW 170.1 billion in 2025 (up 33.4%). Sales grew for three consecutive years from 2023 through 2025, and 2025 was the largest year in the 2022 to 2025 period.

Operating results swung from an operating loss of KRW 8.61 billion in 2022 to operating profit of KRW 3.06 billion in 2023, a turnaround to profit. Operating profit then rose to KRW 6.22 billion in 2024 (up 103.1%) before falling 74.7% to KRW 1.57 billion in 2025.

The operating margin was -58.9% in 2022, 3.3% in 2023, 4.9% in 2024, and 0.9% in 2025. Net income attributable to controlling shareholders was KRW 3.93 billion in 2023, fell to KRW 1.11 billion in 2024, and turned into a net loss of KRW 9.79 billion in 2025.

Consolidated net loss including non-controlling interests was KRW 10.4 billion in 2025. Sales scale expanded, but margins weakened after 2024, and 2025 earnings measures moved into losses.

At the end of 2025, total liabilities were KRW 152.4 billion against total equity of KRW 81.5 billion, of which KRW 62 billion belonged to controlling shareholders. Operating cash flow moved from an inflow of KRW 4.81 billion in 2024 to an outflow of KRW 14.9 billion in 2025.

Quarterly sales rose from KRW 40.9 billion in Q3 2025 to KRW 74.9 billion in Q2 2026, then eased to KRW 68.4 billion in Q3 2026. Operating losses were KRW 664 million in Q1 2026, KRW 2.4 billion in Q2, and KRW 4.98 billion in Q3, three consecutive loss quarters with a widening loss.

Q1 2026 showed net income attributable to controlling shareholders of KRW 5.67 billion despite the operating loss, so non-operating items deserve review in the annual report. Controlling-shareholder net losses followed in Q2 and Q3 2026, and the last four quarters total a net loss of KRW 16.1 billion. The company attributed the operating loss mainly to higher R&D and marketing spending.

05

Industry analysis

Listed Korean pharma and biotech companies fall into two broad groups. One competes on scale through contract manufacturing or biosimilars, while the other proves value through new drug pipelines and licensing.

Keeps Biopharma leans toward the pipeline group, yet its current sales come from anticancer drug distribution and acquired subsidiaries, a mixed structure. In oncology, Idetrexed targets the folate receptor, and the company argues it avoids the toxicity limits of antibody-drug conjugates.

That is the company's own position, and assessments may diverge until clinical results confirm it. In oral delivery, technology that converts injectable peptides into oral forms is drawing attention, and Oraloid is expanding from insulin toward peptides such as GLP-1.

In the battery unit, Battery Solutions' operating profit was reported to have fallen from KRW 3.6 billion to KRW 2.4 billion in the first half of 2026. Compared with other listed peers, the company stands out for high sales growth alongside low margins.

Its distribution business, a cash-generating base, is cited as a factor that can reduce earnings volatility relative to pure drug developers.

06

Outlook

The largest stated goal is KRW 500 billion in consolidated annual sales by the end of 2027, announced on August 14, 2026. That target relies on further M&A and expansion, so whether acquisitions proceed is central.

In the same announcement, the company said operating profit could turn around within the year if cost burdens eased alongside sales growth. However, the operating loss reported for Q3 2026 at KRW 4.98 billion was larger than the KRW 2.4 billion in Q2.

A report by The Bell in August 2026 said profitability could improve as R&D and marketing spending concentrated in the first half declines in the second half. L-Pharm was acquired in February 2026, and its full-period results are expected to be reflected from the second half.

In the pipeline, the company said interim results from the UK combination trial of Idetrexed would be announced starting in the first half of 2027. Oraloid presented preclinical oral insulin data in September 2026 and flagged licensing discussions with global pharma at a US biotech event.

A Battery Solutions IPO had been delayed by dual-listing rules, but guidance allowing exceptions has opened the possibility of a listing. The next checkpoints are the operating margin in the 2026 annual report and the content of the UK interim trial results.

07

Valuation

PER
—
PBR
1.7×
ROE
-24.5%
EPS
-₩811
BPS
₩2,782
Dividend per share
₩0

No earnings-based multiple can be calculated at present. Because the last four quarters show net losses attributable to controlling shareholders, PER is not computed. The price-to-book ratio sits in a range where the market value trades at a premium to net assets.

The split between controlling-shareholder equity and non-controlling interests also matters when reading that ratio. The cash dividend yield is effectively zero, so the case for shareholder returns from cash distributions is weak.

Against listed biopharma peers, earnings-based metrics cannot be used, so comparisons usually rest on asset-based measures and operating indicators such as sales growth. Whether a multiple can be calculated again depends on whether the operating-profit turnaround the company cited actually materializes.

Valuation moves with quarterly results, so the next annual report's income structure is a natural reference point.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Sales growth and a shifting revenue mix

Cumulative sales for the first nine months of 2026 reached KRW 202.8 billion, up 62% year on year, passing full-year 2025 sales within nine months (preliminary, reported November 16, 2026). The pharma and biotech share rose to 40%, changing the revenue mix. On disclosed figures, sales expanded from KRW 14.6 billion in 2022 to KRW 170.1 billion in 2025.

Clinical pipeline progress

Idetrexed is in a combination trial led by the UK Institute of Cancer Research, and domestic Phase 2 IND approval has been reported. In a July 2026 technical report, the Korea Investor Relations Association described the core pipeline's clinical development as proceeding smoothly and cited medium-term growth momentum. The Oraloid platform is expanding from insulin toward GLP-1.

Diversified profit sources from distribution and subsidiaries

The anticancer-focused subsidiary Big Think's cumulative sales for the first nine months of 2026 reached KRW 9.6 billion, nearly triple the prior-year level, and it turned to cumulative operating profit of KRW 300 million.

The L-Pharm acquisition added a distribution channel, and the company said bringing drug distribution in-house can lift margins. That gives the group a broader cash-generating base than a pure drug developer.

09

Bear factors

Widening operating losses and a delayed turnaround

Losses persisted for three straight quarters, with each quarter's loss larger than the one before. The company had projected an operating-profit turnaround within 2026 in August, yet Q3 losses moved in the opposite direction. Cumulative operating loss for the first nine months of 2026 was KRW 8 billion (preliminary).

Rising financial leverage

Debt-to-equity rose from 63.7% in 2022 to 100.2% in 2023, 161.3% in 2024, and 187.0% in 2025. Total liabilities at the end of 2025 were KRW 152.4 billion, above total equity of KRW 81.5 billion.

Operating cash flow turned to an outflow of KRW 14.9 billion in 2025, which narrows room for funding acquisitions and operations from internal cash.

Licensing still at the discussion stage

In June 2026 the company announced attendance at a major biotech event and flagged licensing talks with global big pharma. The UK combination trial's interim results are expected from the first half of 2027, so the pipeline's value is still years from showing up in reported earnings. Short-term results therefore depend more on M&A and distribution profits.

10

Risk factors

M&A integration and subsidiary losses

Successive acquisitions have added sub-subsidiaries, and reports said subsidiaries in the pharma and biotech unit continued to post losses in the first half of 2026. The KRW 500 billion sales goal for the end of 2027 also depends on further acquisitions. If integration is delayed, operating losses could persist longer.

Financial structure and cash flow

Total liabilities at the end of 2025 of KRW 152.4 billion exceed total equity of KRW 81.5 billion, with debt-to-equity at 187.0%. Operating cash flow was an outflow of KRW 14.9 billion in 2025.

With controlling-shareholder net losses totaling KRW 16.1 billion over the last four quarters, any additional funding could bring dilution or higher interest costs.

Clinical regulatory and timing risk

Reports said the company received a supplementary request during the domestic IND process for Idetrexed and resubmitted. Phase 2 entry and interim result timing follow company plans, and delays or results short of expectations could change how the pipeline is valued. The size of any global licensing deal for the oral platform has not been disclosed.

11

What to watch next

  1. By late March 2027

    The 2026 annual report will confirm full-year operating margin and net income attributable to controlling shareholders. It can also show what non-operating items drove the Q1 2026 profit.

  2. Mid-May 2027

    The Q1 2027 quarterly report will show whether operating losses continue. Whether the three-quarter loss streak ends is the test of the turnaround outlook.

  3. First half of 2027

    Check whether the UK combination trial's interim results for Idetrexed are announced and what they show. They would be the first clinical evidence linking the pipeline to value.

  4. End of December 2027

    Check whether the company reaches its KRW 500 billion consolidated sales goal. The path to that target will also show how much it relies on M&A.

12

Overall view

Keeps Biopharma has grown sales quickly, with pharma and biotech M&A at the center. Preliminary cumulative sales for the first nine months of 2026 reached KRW 202.8 billion, passing full-year 2025 sales within nine months, and the pharma and biotech share rose to 40%.

On the other hand, the disclosed operating margin fell to 0.9% in 2025, and operating losses have run for three straight quarters from Q1 to Q3 2026 with a widening gap.

The pipeline centers on the UK combination trial for Idetrexed and the Oraloid oral platform, and interim clinical results and licensing deals still need time. On the financial side, debt-to-equity rose to 187.0%, increasing leverage.

Bullish factors include the shift in revenue mix, pipeline progress, and subsidiaries turning profitable, while bearish factors include widening operating losses and financial burden.

The next checkpoints are the operating margin in the 2026 annual report, whether operating losses persist in Q1 2027, and the interim clinical results in the first half of 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 14 more articles and sources
  1. fnnews.com
  2. supple.kr
  3. view.asiae.co.kr
  4. supple.kr
  5. view.asiae.co.kr
  6. newspim.com
  7. etoday.co.kr
  8. supple.kr
  9. view.asiae.co.kr
  10. etoday.co.kr
  11. m.news.nate.com
  12. view.asiae.co.kr
  13. m.news.nate.com
  14. fnnews.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis